Brief: Antengene Corp Says Australia's TGA Has Registered XPOVIO (Selinexor) For Two Indications
09/03/2022 10:26
March 9 (Reuters) - Antengene Corporation Ltd 6996.HK :
* AUSTRALIA'S THERAPEUTIC GOODS ADMINISTRATION HAS
REGISTERED
XPOVIO (SELINEXOR) FOR TWO INDICATIONS
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106